Still under clinical hold, Fulcrum locks in seasoned commercial leader as CEO

Amber Tong

Fulcrum Therapeutics has recruited a new chief executive well versed in the marketing world amid management upheaval, a full clinical hold for its sickle cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Still under clinical hold, Fulcrum locks in seasoned commercial leader as CEO

Amber Tong

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Still under clinical hold, Fulcrum locks in seasoned commercial leader as CEO